German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay
Authors:
- Jana ManzkeJMJana Manzke
- Raphael StaufRSRaphael Stauf
- Bernd NeumannBNBernd Neumann
- Ernst MolitorErnst Molitor
- Gunnar HischebethGHGunnar Hischebeth
- Michaela SimonMSMichaela Simon
- Jonathan JantschJJJonathan Jantsch
- Jürgen RödelJRJürgen Rödel
- Sören L. BeckerSören L. Becker
- Alexander HalfmannAHAlexander Halfmann
- Thomas A. WichelhausTWThomas A. Wichelhaus
- Michael HogardtMHMichael Hogardt
Open Access
- 19 April 2022
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 11 (5) , 545
Abstract
Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for carbapenemase production and susceptibility against ceftazidime-avibactam. Meropenem-resistant isolates of P. aeruginosa from various clinical materials were collected at 11 tertiary care hospitals in Germany from 2017–2019. Minimum inhibitory concentrations (MICs) were determined via microdilution plates (MICRONAUT-S) of ceftazidime-avibactam and meropenem at each center. Detection of the presence of carbapenemases was performed by PCR or immunochromatography. For meropenem-resistant isolates (n = 448), the MIC range of ceftazidime-avibactam was 0.25–128 mg/L, MIC90 was 128 mg/L and MIC50 was 16 mg/L. According to EUCAST clinical breakpoints, 213 of all meropenem-resistant P. aeruginosa isolates were categorized as susceptible (47.5%) to ceftazidime-avibactam. Metallo-β-lactamases (MBL) could be detected in 122 isolates (27.3%). The MIC range of ceftazidime-avibactam in MBL-positive isolates was 4–128 mg/L, MIC90 was >128 mg/L and MIC50 was 32 mg/L. There was strong variation in the prevalence of MBL-positive isolates among centers. Our in vitro results support ceftazidime-avibactam as a treatment option against infections caused by meropenem-resistant, MBL-negative P. aeruginosa.Keywords
Funding Information
- Merlin Diagnostika (not applicable)
- Pfizer (Germany) (not applicable)
This publication has 17 references indexed in Scilit:
- Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactamInternational Journal of Antimicrobial Agents, 2019
- Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organismsJournal of Antimicrobial Chemotherapy, 2018
- Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosisInternational Journal of Antimicrobial Agents, 2018
- Performance of the Etest for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa toward Ceftazidime-AvibactamJournal of Clinical Microbiology, 2018
- How to manage Pseudomonas aeruginosa infectionsDrugs in Context, 2018
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosisThe Lancet Infectious Diseases, 2018
- Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and WoundsAntimicrobial Agents and Chemotherapy, 2017
- Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methodsJournal of Antimicrobial Chemotherapy, 2017
- Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative OrganismsClinical Therapeutics, 2016
- Metallo-β-Lactamases: the Quiet before the Storm?Clinical Microbiology Reviews, 2005